1. In Vivo
  2. >>Deal-Making

Biosimilar Dealmaking Moves The Needle Forward

 
• By Amanda Micklus

Dealmaking is advancing the biosimilar field. Since 2000, the volume of biosimilar deals has grown at a 15% compound annual rate.

DMHC_1200x675

The establishment of a regulatory approval pathway in the US – via the enactment of the Biologics Price Competition and Innovation Act of 2009 as part of the Affordable Care Act – has given way to approval of the first US biosimilars, two of which have launched to date (Sandoz International GMBH's Zarxio (filgrastim-sndz) and Pfizer Inc.'s Inflectra (infliximab-dyyb). In the European Union, where there has been a regulatory pathway for considerably longer, 23 biosimilars are approved. The potential cost-savings from biosimilars provide incentives to companies to advance these therapeutics. And dealmaking has helped those efforts.

According to "Biosimilars Portfolio and Pipeline Trends, 2016", a new Datamonitor Healthcare report, approximately 128 deals involving biosimilars were signed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Financing Quarterly Statistics, Q2 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

Geopolitical Volatility Not Dimming A Healthy Mid-Term Outlook For Life Sciences Deals

 
• By Ashley Yeo

New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

More from In Vivo

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By Jo Shorthouse

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.